Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311769932> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4311769932 endingPage "163" @default.
- W4311769932 startingPage "162" @default.
- W4311769932 abstract "I read with interest and concern the publication of O'Malley et al. on exceptional responders in the ARIEL3 study of rucaparib maintenance [ [1] O’Malley D.M. et al. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol. Oncol. 2022 Oct 20; S0090-8258 (00575–3. (PMID: 36273926)) Google Scholar ]. Of particular note was the information on therapy related myeloid neoplasia (TMN), particularly in light of recent changes in the regulatory landscape for PARP inhibitors in the treatment of ovarian cancer. TMN reporting traditionally includes the hematologic malignancies myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Clonal hematopoiesis (CH), the accumulation of somatic mutations in hematopoietic stem cells and a precursor to myeloid malignancies, is not easily measured and is not routinely reported. TMN have an exceedingly poor prognosis, thus they may contribute to worsened overall survival, even in the setting of improved ovarian cancer-specific survival (i.e. improved PFS) in individuals treated with PARP inhibitors. Response to letter to the editor “AML and MDS associated with PARP inhibitor treatment of ovarian cancer”Gynecologic OncologyVol. 171PreviewWe would like to comment on the letter from Dr. Armstrong related to our recent article published in this journal [1]. We reported exploratory analyses that identified a subset of patients who achieved an exceptional response to rucaparib maintenance therapy within the ARIEL3 trial. With long-term outcome data now available for both the upfront and recurrent ovarian cancer settings, it is known that patients receiving PARPi therapy are at heightened risk of developing MDS/AML [2,3]. Indeed, the letter from Dr Armstrong provides a comprehensive and valuable summary of MDS/AML rates observed in PARPi maintenance studies (including ARIEL3). Full-Text PDF" @default.
- W4311769932 created "2022-12-28" @default.
- W4311769932 creator A5090143508 @default.
- W4311769932 date "2023-04-01" @default.
- W4311769932 modified "2023-10-04" @default.
- W4311769932 title "AML and MDS associated with PARP inhibitor treatment of ovarian cancer" @default.
- W4311769932 cites W2519148856 @default.
- W4311769932 cites W2935541805 @default.
- W4311769932 cites W2975141952 @default.
- W4311769932 cites W2994977341 @default.
- W4311769932 cites W3006801800 @default.
- W4311769932 cites W3113077828 @default.
- W4311769932 cites W3120285006 @default.
- W4311769932 cites W3164090175 @default.
- W4311769932 cites W3195384363 @default.
- W4311769932 cites W4220749886 @default.
- W4311769932 cites W4236289131 @default.
- W4311769932 cites W4281666355 @default.
- W4311769932 doi "https://doi.org/10.1016/j.ygyno.2022.11.027" @default.
- W4311769932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36528399" @default.
- W4311769932 hasPublicationYear "2023" @default.
- W4311769932 type Work @default.
- W4311769932 citedByCount "1" @default.
- W4311769932 countsByYear W43117699322023 @default.
- W4311769932 crossrefType "journal-article" @default.
- W4311769932 hasAuthorship W4311769932A5090143508 @default.
- W4311769932 hasConcept C104317684 @default.
- W4311769932 hasConcept C121608353 @default.
- W4311769932 hasConcept C126322002 @default.
- W4311769932 hasConcept C143998085 @default.
- W4311769932 hasConcept C182979987 @default.
- W4311769932 hasConcept C185592680 @default.
- W4311769932 hasConcept C2778729363 @default.
- W4311769932 hasConcept C2779138821 @default.
- W4311769932 hasConcept C2779282312 @default.
- W4311769932 hasConcept C2780007613 @default.
- W4311769932 hasConcept C2780427987 @default.
- W4311769932 hasConcept C2780817109 @default.
- W4311769932 hasConcept C55493867 @default.
- W4311769932 hasConcept C71924100 @default.
- W4311769932 hasConcept C82381507 @default.
- W4311769932 hasConceptScore W4311769932C104317684 @default.
- W4311769932 hasConceptScore W4311769932C121608353 @default.
- W4311769932 hasConceptScore W4311769932C126322002 @default.
- W4311769932 hasConceptScore W4311769932C143998085 @default.
- W4311769932 hasConceptScore W4311769932C182979987 @default.
- W4311769932 hasConceptScore W4311769932C185592680 @default.
- W4311769932 hasConceptScore W4311769932C2778729363 @default.
- W4311769932 hasConceptScore W4311769932C2779138821 @default.
- W4311769932 hasConceptScore W4311769932C2779282312 @default.
- W4311769932 hasConceptScore W4311769932C2780007613 @default.
- W4311769932 hasConceptScore W4311769932C2780427987 @default.
- W4311769932 hasConceptScore W4311769932C2780817109 @default.
- W4311769932 hasConceptScore W4311769932C55493867 @default.
- W4311769932 hasConceptScore W4311769932C71924100 @default.
- W4311769932 hasConceptScore W4311769932C82381507 @default.
- W4311769932 hasLocation W43117699321 @default.
- W4311769932 hasLocation W43117699322 @default.
- W4311769932 hasOpenAccess W4311769932 @default.
- W4311769932 hasPrimaryLocation W43117699321 @default.
- W4311769932 hasRelatedWork W1581697485 @default.
- W4311769932 hasRelatedWork W2041580433 @default.
- W4311769932 hasRelatedWork W2064665154 @default.
- W4311769932 hasRelatedWork W2150998544 @default.
- W4311769932 hasRelatedWork W2157783208 @default.
- W4311769932 hasRelatedWork W2404178125 @default.
- W4311769932 hasRelatedWork W2406230970 @default.
- W4311769932 hasRelatedWork W2789081643 @default.
- W4311769932 hasRelatedWork W3149464131 @default.
- W4311769932 hasRelatedWork W4283022593 @default.
- W4311769932 hasVolume "171" @default.
- W4311769932 isParatext "false" @default.
- W4311769932 isRetracted "false" @default.
- W4311769932 workType "article" @default.